Showing results (771-780 of 795) with videos related to

Sort By:
Pageof 80
Pharmacoepidemiology and Drug Safety|July 6, 2012
Safety of saxagliptin: rationale for and design of a series of postmarketing observational studiesVincent Lo Re, Kevin Haynes, Eileen E Ming, et al.
Veterinary Clinical Pathology|November 29, 2007
Establishment of the European College of Veterinary Clinical Pathology (ECVCP) and the current status of veterinary clinical pathology in EuropeP J O'Brien, C Fournel-Fleury, A P Bolliger, et al.
Bjpsych Open|December 12, 2024
A proof-of-concept analysis of data from the first NHS clinic for young adults with comorbid cannabis use and psychotic disordersMarta Di Forti, Benjamin W Bond, Edoardo Spinazzola, et al.
Psychological Medicine|April 29, 2020
Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controlsMusa Sami, Diego Quattrone, Laura Ferraro, et al.
Frontiers in Psychiatry|June 7, 2021
Supporting Future Cannabis Policy - Developing a Standard Joint Unit: A Brief Back-Casting ExerciseHugo López-Pelayo, Silvia Matrai, Mercè Balcells-Olivero, et al.
Cold Spring Harbor Molecular Case Studies|October 13, 2019
Enrichment of heterozygous germline RECQL4 loss-of-function variants in pediatric osteosarcomaJamie L Maciaszek, Ninad Oak, Wenan Chen, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|March 21, 2022
Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) TaskforceJerome Sarris, Arun Ravindran, Lakshmi N Yatham, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|January 15, 2025
Cannabis Use Cessation and the Risk of Psychotic Disorders: A Case-Control Analysis from the First Episode Case-Control EU-GEI WP2 Study: L'arrêt de l'utilisation du cannabis et le risque de troubles psychotiques: Une analyse cas-témoins tirée de l'étude cas-témoins EU-GEI WP2 centrée sur les premiers épisodes psychotiquesBenjamin W Bond, Bea Duric, Edoardo Spinazzola, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|May 20, 2026
The American Society of Clinical Psychopharmacology task force consensus statement on the deprescribing of stimulant medications in adults with ADHD✰David W Goodman, Rajnish Mago, Leslie Citrome, et al.
The Lancet. Psychiatry|March 24, 2019
The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control studyMarta Di Forti, Diego Quattrone, Tom P Freeman, et al.
Pageof 80